Update on clinical, pathophysiological and therapeutic aspects in ANCA-associated vasculitides

Current Drug Discovery Technologies

Volumn 6, Issue 4, 2009, Pages 241-251

  Lamprecht, Peter ^a   Holle, Julia ^a   Gross, Wolfgang L ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; ALPHA INTERFERON; ATACICEPT; AZATHIOPRINE; BAFILOMYCIN; BELIMUMAB; CD20 ANTIBODY; CYCLOPHOSPHAMIDE; EPRATUZUMAB; ETANERCEPT; FOLIC ACID; IMMUNOGLOBULIN; INFLIXIMAB; INTERLEUKIN 15; INTERLEUKIN 17; LEFLUNOMIDE; MEPOLIZUMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; OCRELIZUMAB; OFATUMUMAB; PLACEBO; PREDNISOLONE; PROTEINASE ACTIVATED RECEPTOR 2; RITUXIMAB; STEROID; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNINDEXED DRUG;

ANCA ASSOCIATED VASCULITIS; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; AUTOIMMUNITY; BIOLOGICAL THERAPY; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; CLINICAL TRIAL; COMPLEMENT DEPENDENT CYTOTOXICITY; CROHN DISEASE; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; GENETIC PREDISPOSITION; GRANULOMATOSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INFECTION; INFLAMMATION; INJECTION SITE REACTION; LEUKOENCEPHALOPATHY; LYMPHOID TISSUE; MICROSCOPIC POLYANGIITIS; MULTIPLE CYCLE TREATMENT; NATURAL KILLER T CELL; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; RECOMMENDED DRUG DOSE; REMISSION; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SMALL VESSEL VASCULITIS; STAPHYLOCOCCUS AUREUS; SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 CELL; TH17 CELL; TH2 CELL; TREATMENT DURATION; WEGENER GRANULOMATOSIS;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, MONOCLONAL; AUTOIMMUNITY; BIOLOGICAL PRODUCTS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; MODELS, IMMUNOLOGICAL; QUANTITATIVE TRAIT LOCI;

EID: 70449727690     PISSN: 15701638     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016309789868994     Document Type: Review

References (104)

1. Little MA, Nightingale P, Verburgh CA, et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 2009 Jul 1. [Epub ahead of print].
2. Phillip R, Luqmani R. Mortality in systemic vasculitis: a systematic review. Clin Exp Rheumatol 2008; 26(5 Suppl 51): S94-104.
3. Holle JU, Gross WL. ANCA-associated vasculitides: Pathogenetic aspects and current evidence-based therapy. J Autoimmun 2009; 32: 163-171
4. Lamprecht P, Till A, Steinmann J, Aries PM, Gross WL. Current state of biological in the management of systemic vasculitis. Ann NY Acad Sci 2007; 1110: 261-270 (Pubitemid 350043015)
5. Csernok E, Lamprecht P, Gross WL. Diagnostic significance of ANCA in vasculitis. Nat Clin Pract Rheumatol 2006; 2: 174-175
6. Fries JF, Hunder GG, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary. Arthritis Rheum 1990; 33: 1135-1136
7. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994, 37: 187-192
8. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of primary small vessel vasculitis. Ann Rheum Dis 2009; 68: 310-317
9. Hellmich B, Flossman O, Gross WL, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: Focus on anti-neutrophil cytoplasm antibodyassociated vasculitis. Ann Rheum Dis 2007; 66: 605-617 (Pubitemid 46707128)
10. Jayne D. Challenges in the management of microscopic polyangiitis. Curr Opin Rheumatol 2008; 20: 3-9.
11. Sable-Fourtassou R, Cohen P, Mahr A, et al. Antineutrophil cytoplasmic antibodies and the Churg Strauss syndrome. Ann Intern Med 2005; 143: 632-638 (Pubitemid 41552527)
12. Reinhold-Keller E, Beuge N, Latza U, et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: Long-term outcome in 155 patients. Arthritis Rheum 2000; 43: 1021-1032 (Pubitemid 30368179)
13. Guillvevin L, Durand-Gasselin B, Cevallos R, et al. Microscopic polyangiitis: Clinical and laboratory findings in eighty five patients. Arthritis Rheum 1999; 42: 421-430 (Pubitemid 29136088)
14. Kradin RL, Mark EJ. A 48-year-old man with a cough and bloody sputum. N Engl J Med 2002; 346: 1892-1899
15. Holl-Ulrich K, Both M, Gottschlich S, Gross WL, Aries PM, Lamprecht P. Clinical images: Saddle-nose deformity caused by destructive granulomatous inflammation in Wegener's granulomatosis. Arthritis Rheum 2008; 58: 834.
16. Müller A, Holl-Ulrich K, Lamprecht P, Gross WL. Germinal centre- like structures in Wegener's granulomatosis: The morphological basis for autoimmunity? Rheumatology 2008; 47: 1111-1113
17. Voswinkel J, Mueller A, Kraemer JA, et al. B-lymphocyte maturation in Wegener's granulomatosis: A comparative analysis of VH genes from endonasal lesions. Ann Rheum Dis 2006; 65: 859-864
18. Stegeman CA, Cohen-Tervaert JW, Sluiter WJ, Manson WL, de Jong PE, Kallenberg CGM. Association of chronic nasal carriage of staphylococcus aurous and higher relapse rates in Wegener granulomatosis. Ann Intern Med 1994; 120: 12-17.
19. Stegman CA, Cohen-Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co- Trimoxazole Wegener Study Group. New Engl J Med 1996; 335: 16-20.
20. Popa ER, Stegeman CA, Abdulahad WH, et al. Staphylococcal toxic-shock-syndrome-toxin-1 as a risk factor for disease relapse in Wegener's granulomatosis. Rheumatology (Oxford) 2007; 46: 1029-1033
21. Wertheim HF, Melles DC, Vos MC, et al. The role of nasal carriage in staphylococcus aureus infections. Lancet Infect Dis 2005; 5: 751-762 (Pubitemid 41688980)
22. Hurtado PR, Jeffs L, Nitschke J, et al. CpG oligodeoxynucleotide stimulates production of anti-neutrophil cytoplasmic antibodies in ANCA associated vasculitis. BMC Immunol 2008; 9: 34.
23. Tadema H, Abdulahad WH, Lepse N, Stegeman CA, Kallenberg CGM, Heeringa P. CpG triggers ANCA production by blood-derived B-cells from ANCA-associated vasculitis patients in clinical remission. APMIS 2009; 117(Suppl 127): 116.
24. Csernok E, Ai M, Gross WL, et al. Wegener autoantigen induces maturation of dendritic cells and licenses them for Th1 priming via the protease-activated receptor-2 pathway. Blood 2006; 107: 4440-4448 (Pubitemid 43801371)
25. Novick D, Rubinstein M, Azam T, et al. Proteinase 3 is an IL-32 binding protein. Proc Natl Acad Sci USA 2006; 103: 3316-3321
26. Pederzoli M, Kantari C, Gausson V, Moriceau S, Witko-Sarsat V. Proteinase-3 induces procaspase-3 activation in the absence of apoptosis: Potential role of this compartmentalized activation of membrane-associated procaspase-3 in neutrophils. J Immunol 2005; 174: 6381-6390 (Pubitemid 40663831)
27. Pfister H, Ollert M, Fröhlich LF, et al. Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo. Blood 2004; 104: 1411-1418 (Pubitemid 39166519)
28. Kessenbrock K, Fröhlich L, Sixt M, et al. Proteinase 3 and neutrophil elastase enhance inflammation in mice by inactivating antiinflammatory progranulin. J Clin Invest 2008; 118: 2438-2447 (Pubitemid 351949772)
29. Capraru D, Müller A, Csernok E, et al. Expansion of circulating NKG2D+ effector memory T-cells and expression of NKG2D-ligand MIC in granulomaous lesions in Wegener's granulomatosis. Clin Immunol 2008; 127: 144-150
30. Kessenbrock K, Krumbholz M, Schönermarck U, et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med 2009; 15: 623-625
31. Yano T, Kurata S. An unexpected twist for autophagy in Crohn's disease. Nat Immunol 2009; 10: 134-136
32. Ullrich S, Gustke H, Lamprecht P, et al. Severely impaired respiratory ciliar function in Wegener's Granulomatosis. Ann Rheum Dis 2009; 68: 1067-1071
33. Zinkernagel RM. Antiinfection immunity and autoimmunity. Ann NY Acad Sci 2002; 958: 3-6.
34. Lang KS, Recher M, Junt T, et al. Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat Med 2005; 11: 138-145 (Pubitemid 40321348)
35. Csernok E, Trabandt A, Muller A, et al. Cytokine profiles in Wegener's granulomatosis: predominance of type 1 (Th1) in the granulomatous inflammation. Arthritis Rheum 1999; 42: 742-750 (Pubitemid 29171995)
36. Müller A, Trabandt A, Gloeckner-Hofmann K, et al. Localized Wegener's granulomatosis: Predominance of CD26 and IFN-gamma expression. J Pathol 2000; 192: 113-120
37. Balding CE, Howie AJ, Drake-Lee AB, Savage CO. Th2 dominance in nasal mucosa in patients with Wegener's granulomatosis. Clin Exp Immunol 2001; 125: 332-339
38. Kiene M, Csernok E, Müller A, Metzler C, Trabandt A, Gross WL. Elevated interleukin-4 and interleukin-13 production by T cell lines from patients with Churg-Strauss syndrome. Arthritis Rheum 2001; 44: 469-473
39. King WJ, Brooks CJ, Holder R, Hughes P, Adu D, Savage CO. T lymphocyte responses to anti-neutrophil cytoplasmic autoantibody (ANCA) antigens are present in patients with ANCA-associated systemic vasculitis and persist during disease remission. Clin Exp Immunol 1998; 112: 539-546 (Pubitemid 28267439)
40. Van der Geld YM, Huitema MG, Franssen CF, van der Zee R, Limburg PC, Kallenberg CG. In vitro T lymphocyte responses to proteinase 3 (PR3) and linear peptides of PR3 in patients with Wegener's granulomatosis (WG). Clin Exp Immunol 2000; 122: 504-513
41. Winek J, Mueller A, Csernok E, Gross WL, Lamprecht P. Frequency of proteinase 3 (PR3)-specific autoreactive T cells determined by cytokine flow cytometry in Wegener's granulomatosis. J Autoimmun 2004; 22: 79-85. (Pubitemid 38050216)
42. Popa ER, Franssen CF, Limburg PC, Huitema MG, Kallenberg CG, Cohen Tervaert JW. In vitro cytokine production and proliferation of T cells from patients with anti-proteinase 3- and antimyeloperoxidase- associated vasculitis, in response to proteinase 3 and myeloperoxidase. Arthritis Rheum 2002; 46: 1894-1904
43. Abdulahad WH, Stegeman CA, Limburg FC, Kallenberg CG. Skewed distribution of Th17 lymphocytes in patients with Wegener's granulomatosis in remission. Arthritis Rheum 2008; 58: 2196-2205
44. Abdulahad WH, Stegeman CA, van der Geld YM, et al. Functional defect of circulating regulatory CD4+ T-cells in patients with Wegener's granulomatosis in remission. Arthritis Rheum 2007; 56: 2080-2091
45. Harper L, Savage COS. Pathogenesis of ANCA-associated systemic vasculitis. J Pathol 2000; 190: 349-359
46. Gross WL. Immunopathology and new therapeutic considerations in ANCA-associated vasculitides. Autoimmun Rev 2004; 3(Suppl.1): S47-48.
47. Rarok AA, Stegeman CA, Limburg PC, Kallenberg CG. Neutrophil membrane expression of proteinase 3 (PR3) is related to relapse in PR3-ANCA-associated vasculitis. J Am Soc Nephrol 2002; 13: 2232-2238
48. Ben-Smith A, Dove SK, Martin A, Wakelam MJ, Savage CO. Antineutrophil cytoplasm autoantibodies from patients with systemic vasculitis activate neutrophils through distinct signaling cascades: comparison with conventional Fc-gamma receptor ligation. Blood 2001; 98: 1448-1455
49. Kettritz R, Choi M, Butt W, et al. Phosphatidylinositol 3-kinase controls antineutrophil cytoplasm antibodies-induced respriratory burst in human neutrophils. J Am Soc Nephrol 2002; 13: 1740-1749 (Pubitemid 34700598)
50. Williams JM, Pettitt TR, Powell W, Grove J, Savage CO, Wakelam MJ. Antineutrophil cytoplasm antibody-stimulated neutrophil adhesion depends on diacylglycerol kinase-catalyzed phosphatidic acid formation. J Am Soc Nephrol 2007; 18: 1112-1120 (Pubitemid 46536897)
51. Kettritz R, Schreiber A, Luft FC, Haller H. Role of mitogen-activated protein kinases in activation of human neutrophils by antineutrophil cytoplasm antibodies. J Am Soc Nephrol 2001; 12: 37-46. (Pubitemid 32056787)
52. Choi M, Rolle S, Rane M, Haller H, Luft FC, Kettritz R. Extracellular signal-regulated kinase inhibition by statins inhibits neutrophil activation by ANCA. Kidney Int 2003; 63: 96-106. (Pubitemid 35463910)
53. Von Vietinghoff S, Tunnemann G, Eulenberg C, et al. NB1 mediates surface expression of the ANCA antigen proteinase 3 on human neutrophils. Blood 2007; 109: 4487-4493 (Pubitemid 46743419)
54. Jerke U, Dittmar G, Rolle S, Luft F, Kettritz. Complement receptor C3 (Mac-1) is an adaptor for NB1 (CD177)-mediated neutrophil signaling. APMIS 2009; 117(Suppl 127): 120.
55. Hu N, Westra J, Huitema MG, et al. Coexpression of CD177 and membrane proteinase 3 on neutrophils in antineutrophil cytoplasmic autoantibody- associated systemic vasculitis: Anti-proteinase 3- mediated neutrophil activation is independent of the role of CD177-expressing neutrophils. Arthritis Rheum 2009; 60: 1548-1557
56. Radford DJ, Luu NT, Hewins P, Nash G, Savage COS. Antineutrophil antibodies stabilze adehesion and promote migration of flowing neutrophils on endothelial cells. Arthritis Rheum 2001; 44: 2851-2861 (Pubitemid 34016205)
57. Cockwell P, Brooks CJ, Adu D, Savage COS. Interleukin-8: A pathogenetic role in antineutrophil cytoplasmic autoantibody-associated glomerulonephritis. Kidney Int 1999; 55: 852-863 (Pubitemid 29100697)
58. Little MA, Smyth CL, Yadav R, et al. Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. Blood 2005; 106: 2050-2058 (Pubitemid 41291719)
59. Xiao H, Heeringa P, Hu P, et al. Antineutrophil cytoplasmic auto-antibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002; 110: 955-963
60. Huugen D, Xiao H, van Esch A, et al. Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha. Am J Pathol 2005; 167: 47-58. (Pubitemid 40884769)
61. Little MA, Bhangal G, Smyth L, et al. Therapeutic effect of anti- TNF- antibodies in an experimental model of anti-neutrophil cytoplasm antibody-associated systemic vasculitis. J Am Soc Nephrol 2006; 17: 160-169
62. Little MA, Smyth L, Salama AD, et al. Experimental autoimmune vasculitis: An animal model of anti-neutrophil cytoplasmic autoantibody- associated systemic vasculitis. Am J Pathol 2009; 174: 1212-1220
63. Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R, Gross WL. Stable incidence of primary systemic vasculitides over five years: Results from the German vasculitis register. Arthritis Rheum 2005; 53: 93-99. (Pubitemid 40216357)
64. Jagiello P, Gross WL, Epplen JT. Complex genetics of Wegener's granulomatosis. Autoimmun Rev 2005; 4: 42-47.
65. Heckmann M, Holle JU, Arning L, et al. The Wegener's granulomatosis quantitative trait locus on chromosome 6p21.3 as characterized by tagSNP genotyping. Ann Rheum Dis 2008; 67: 972-979 (Pubitemid 351956660)
66. Vaglio A, Martorana D, Maggiore U, et al. HLA-DRB4 as a genetic risk factor for Churg-Strauss syndrome. Arthritis Rheum 2007; 56: 3159-3166 (Pubitemid 47502764)
67. Wieczorek S, Hellmich B, Arning L, et al. Functionally relevant variations of the interleukin-10 gene are associated with antineutrophil cytoplasmic antibody-negative Churg-Strauss syndrome, but not with Wegener's granulomatosis. Arthritis Rheum 2008; 58: 1839-1848 (Pubitemid 351847539)
68. Jagiello P, Aries P, Arning L, et al. The PTPN22 620W allele is a risk factor for Wegener's granulomatosis. Arthritis Rheum 2005; 52: 4039-4043 (Pubitemid 41798244)
69. Fanciulli M, Norsworthy PJ, Petretto E, et al. FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity. Nat Genet 2007; 39: 721-723 (Pubitemid 46848593)
70. Stone JH, Uhlfelder ML, Hellmann DB, et al. Etanercept combined with conventional treatment in Wegener's granulomatosis: A six-months open-label trial to evaluate safety. Arthritis Rheum 2001; 44: 1149-1154
71. The Wegener's Granulomatosis Etanercept (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352: 351-361
72. Mukhtyar C, Luqmani R. Current state of tumour necrosis factor blockade in Wegener's granulomatosis. Ann Rheum Dis 2005; 64(Suppl.4): 31-36. (Pubitemid 41532014)
73. Gause A, Arbach O, Lamprecht P. Treatment of primary systemic vasculitis with TNF- antagonists. Z Rheumatol 2003; 62: 228-234 (Pubitemid 36829467)
74. Van den Brande JM, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003; 124: 1774-1785 (Pubitemid 36666774)
75. Keogh K, Wylam M, Stone J, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52: 262-268 (Pubitemid 40129256)
76. Jones RB, Ferraro AJ, Chaudhry AN, et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic anti-body- associated vasculitis. Arthritis Rheum 2009; 60: 2156-2168
77. Chung SA, Seo P. Advances in the use of biologic agents for the treatment of systemic vasculitis. Curr Opin Rheumatol 2009; 21: 3-9.
78. Aldebert D, Lamkhioued B, Desaint C, et al. Eosinophils express a functional receptor for interferon alpha: Inhibitory role of interferon alpha on the release of mediators. Blood 1996; 87: 2354-2360 (Pubitemid 26086877)
79. Morita M, Lamkhioued B, Soussi Gounni A, et al. Induction by interferons of human eosinophil apoptosis and regulation by interleukin- 3, granulocyte/macrophage-colony stimulating factor and interleukin- 5. Eur Cytokine Netw 1996; 7: 725-732 (Pubitemid 27056450)
80. Metzler C, Schnabel A, Gross WL, Hellmich B. A phase II study of interferon-alpha for the treatment of refractory Churg-Strauss syndrome. Clin Exp Rheumatol 2008; 26(3 Suppl 49): S35-40.
81. Rothenberg ME, Klion AD, Roufosse FE, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008; 358: 1215-1228
82. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009; 360: 985-993
83. Genovese MC, Kaine JL, Lowenstein MB, et al. Ocrelizumab, a humanized anti-CD20 antibody, in the treatment of pateints with rheumatoid arthritis: A phase I/II ranodmized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum 2008; 58: 2652-2661
84. Østergaard M, Baslund B, Rigby W, et al. Ofatumumab (HuMax- CD20), a fully human CD20 monoclonal antibody, in the treatment of rheumatoid arthritis. Early results from an ongoing, doubleblind, randomized, placebo controlled clinical trial. Ann Rheum Dis 2007; 66: 124.
85. Steinfeld SD, Tant L, Burmester GR, et al. Epratuzumab (humanized anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study. Arthritis Res Ther 2006; 8: R129.
86. Dörner T, Kaufmann J, Wegener WA, et al. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006; 8: R74.
87. Levesque MC. Translational mini-review series on B cell-directed therapies: recent advances in B-cell-directed biological therapies for autoimmune disorders. Clin Exp Immunology 2009; 157: 198-208.
88. Bosello S, Youninou P, Daridon C, et al. Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis. J Rheumatol 2008; 35: 1256-1264 (Pubitemid 352000768)
89. Pers JO, Daridon C, Devauchelle V, et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann NY Acad Sci 2005; 1050: 34-39. (Pubitemid 41129420)
90. Mariette X, Roux S, Zhang J, et al. The level of Blys (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rehum Dis 2003; 62: 168-171 (Pubitemid 36135394)
91. Krumbholz M, Specks U, Wick M, et al. BAFF is elevated in serum of patients with Wegener's granulomatosis. J Autoimm 2005; 25: 298-302. (Pubitemid 41642976)
92. Stohl W, Xu D, Kim KS, et al. BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predis-position to systemic lupus erythematosus. Arthritis Rheum 2005; 52: 2080-2091 (Pubitemid 40994331)
93. Ginzler E, Furie R, Wallace D, et al. Novel combined response endpoint shows that belimumab (fully human monoclonal antibody to B-lymphocyte stimulator [BLAYS]) improves or stabilizes SLE disease activity in a phase 2 trial. Ann Rheum Dis 2007; 66(Suppl): 56.
94. Chatham W, Aranow C, Furie R, et al. Progressive normalization of autoantibody, immunoglobulin, and complement levels over 3 years of belimumab (fully human monoclonal antibody to BLYS) therapy in sytsemic lupus erythematosus (SLE) patients. Ann Rheum Dis 2008; 67(Suppl. II): 217.
95. Tak PP, Thrulings RM, Rossier C, et al. Atacicept in patients with rheumatoid arthritis: Results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum 2008; 58: 61-72.
96. Dall' Era M, Chakravarty E, Wallace D, et al. Reduced B-lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007; 56: 4124-4150 (Pubitemid 350262342)
97. Shaw M, Del Giudice J, Trapp R, et al. The safety, pharmacokinetics and pharmacodynamic effects of repeated doses of BR3-Fc fusion protein in patients with rheumatoid arthritis. Arthritis Rheum 2007; 56: S568-69.
98. Goeb V, Bunch MH, Vital EM, et al. Costimulation blockade in rheumatic diseases: Where we are? Curr Opin Rheumatol 2009; 21: 244-250
99. Badger AM, Griswold DE, Kapadia R, et al. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthritis Rheum 2000; 43: 175-183 (Pubitemid 30368227)
100. Zarbock A, Lowell CA, Lay K. Spleen tyrosine kinase Syk is necessary for E-selection-induced alpha(L)beta2 integrin-mediated rolling on intercellular adhesion molecule-1. Immunity 2007; 26: 773-783
101. Hewins P, Williams JM, Wakelam MJ, et al. Activation of Syk in neutrophils by antineutrophil cytoplasm antiobodies occurs via Fcgamma receptors and CD18. J Am Soc Nephrol 2004; 15: 796-808. (Pubitemid 38294811)
102. Breedveld FC, Bloom BJ, Coombs J, et al. Six weeks of treatment of active rheumatoid arthritis with an orally active inhibitor of janus kinse 3, CP-690,550, is associated with dose-dependent increases in remission rates and improvement in the CDAI and SDAI. Ann Rheum Dis 2007; 66(Suppl 2): 441.
103. Van der Heijden JW, Oelremans R, Lems WF, et al. The proteasome inhibitor bortezomib inhibits the release of NFKappaBinducible cytokines and induces apoptosis of activated T-cells from rheumatoid arthritis patients. Clin Exp Rheumatol 2009; 27: 92-98.
104. Neubert K, Meister S, Moser K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008; 14: 748-755 (Pubitemid 351951516)